Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Next Page

Page Background

Is there still a room for crizotinib in first-

line setting in

ALK

-positive NSCLC

patients?

Jordi Remon Masip

CIOCC HM Delfos Barcelona

@JordiRemon